Crossmark

A pharmacovigilance analysis of abrocitinib-related skin adverse events based on the FDA Adverse Event Reporting System (FAERS)

Crossref DOI link: https://doi.org/10.1007/s00403-025-03959-9

Published Online: 2025-02-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Huang, Min https://orcid.org/0009-0005-2788-1287
Li, Peng https://orcid.org/0009-0009-1768-7172
License Information

Text and Data Mining valid from 2025-02-15

Version of Record valid from 2025-02-15
More Information

Article History

Received: 4 December 2024

Revised: 10 December 2024

Accepted: 3 February 2025

First Online: 15 February 2025

Declarations

:

: The authors declare no competing interests.